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Current Status of Smallpox Vaccine
To the Editor: The possible use of smallpox virus
as a weapon by terrorists has stimulated growing
international concern and led to a recent review
by the World Health Organization of the global
availability of smallpox vaccine. This review
found approximately 60 million doses worldwide,
with little current vaccine manufacture, al-
though limited vaccine seed remains available (1).
Ongoing discussions in the United States
suggest that the national stockpile should
contain at least 40 million doses to be held in
reserve for emergency use, including in case of a
terrorist release of smallpox virus (OToole, this
issue, pp. 540-6).
The current U.S. stockpile contains approxi-
mately 15.4 million doses of vaccinia vaccine
(Dryvax) made from the New York City Board of
Health strain of vaccinia and was produced by
Wyeth Laboratories in 13 separate lots. The
vaccine is lyophylized in glass vials with rubber
stoppers and sealed with a metal band. When
rehydrated, each vial contains 100 doses and has
a potency of at least 108 plaque-forming units
(pfu)/ml. Some vials of the vaccine stockpile have
shown elevated moisture levels and thus failed
routine quality control testing; however, the
vaccine in these vials remains potent, and the
failed lots have not been discarded.
The diluent used to rehydrate the vaccine
contains brilliant green, which makes the
vaccine easier to visualize when administered
with bifurcated needles. Over time, the brilliant
green has deteriorated, and most of the available
diluent does not pass quality control. Discussions
are under way with Wyeth to begin production of
sufficient new diluent for the entire stockpile.
The vaccine is administered by superficial
inoculation (scarification) with a bifurcated
needle. Fewer than 1 million bifurcated needles
are held as part of the stockpile. As with the
diluent, Wyeth has been requested to produce
additional bifurcated needles.
Vaccinia virus produces adverse reactions in
a small percentage of vaccinated persons.
Adverse reactions are treated with vaccinia
immune globulin (VIG), currently only available
from Baxter Healthcare Corporation (5,400 vials
of VIG in stock). Each vial contains 5 ml of VIG;
the recommended dose for postvaccine complica-
tions is 0.6 ml per kg of body weight. This volume
is sufficient to treat adverse reactions in
approximately 675 adults. Further, the entire
stockpile of VIG has been placed on hold while
the cause of a slight pink discoloration is
investigated. Until the cause of the discoloration
is determined or another approved supply of VIG
is obtained, no vaccinia vaccine is being released.
While unknown, the rate of adverse reactions in
todays population is likely to be greater than
seen during the global eradication campaign
because of recent increases in the number of
immunocompromised persons. The Department
of Defense has recently contracted the process-
ing of new lots of VIG (to be administered
intravenously rather than by the intramuscular
route like existing VIG stocks); however,
maintaining adequate stocks of VIG will remain
a challenge.
In the event of release of smallpox virus,
persons at high risk and persons exposed but not
yet showing clinical illness would be vaccinated
immediately. Intensive case detection and
vaccination of contacts and other persons at risk
would follow. All vaccine, including lots retained
after failed quality control tests, would be made
available for emergency use. Previous studies
have found that more than 90% of susceptible
persons respond to vaccinia virus with a titer of
107 pocks/ml (2). In an emergency, consideration
would be given to diluting the existing vaccine as
much as 10-fold, so that each vial could
conceivably contain 1,000 doses of vaccine,
rather than the current 100 doses. The present
vaccine container is sufficiently large to
accommodate the added diluent. The absence of
sufficient quantities of VIG to protect against
adverse reactions during a mass immunization
campaign would necessitate careful screening of
those receiving the vaccine; some persons with
adverse reactions would likely go untreated.
While the intentional release of smallpox
virus would represent a global emergency, the
existing national stockpile could be effectively
used to limit the spread of disease and buy time
while the pharmaceutical industry begins
emergency vaccine production.
James W. LeDuc and John Becher
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West Nile Fever in Czechland
To the Editor: After heavy rains in July 1997,
extensive floods occurred along the Morava
River, Czech Republic. Populations of Aedes
mosquitoes increased rapidly in the flooded
areas, prompting surveillance for mosquito-
borne virus infections in the Breclav area, South
Moravia. We collected 11,334 female mosquitoes
(9,100  Aedes vexans, 917 Ae. cinereus, 11
Ae. cantans, 1,074 Ae. sticticus, and 232 Culex p.
pipiens) from July through September 1997 and
tested them for virus in 117 monospecific pools
by intracranial inoculation of suckling mice.
Seven virus isolates were obtained and identified
by complement-fixation and neutralization tests.
Six isolates (five from Ae. vexans, one from Ae.
cinereus) were identified as the bunyavirus
Tahyna, California serogroup, and one (strain
97-103 from 57 C. p. pipiens collected at Lanzhot,
48o40'N, 16o56'E, on September 17) was
identified as the flavivirus West Nile (1). A
crossed comparison of 97-103 and topotype Eg-
101 (2) West Nile virus strains and their antisera
(prepared in mice by three intraperitoneal doses
at weekly intervals) by plaque reduction
neutralization (PRN) on XTC-2 cells (3,4) showed
their antigenic relationships: reciprocal titers of
homologous/heterologous sera were 512/512 in
Eg-101 and 512/64 in 97-103. Strain 97-103 has
lower virulence than Eg-101 in that it does not
kill adult ICR mice and may represent a subtype
of West Nile virus.
Blood samples were obtained from 619
persons seeking treatment at hospital and
outpatient clinics in the Breclav area from June
23 through September 29, 1997. Sera were
inactivated at 56°C for 30 minutes, diluted 1:8,
and assayed by PRN for antibodies against c. 30
plaque-forming units (PFU) per well of West Nile
virus strains Eg-101 and 97-103. All sera causing
90% reduction of PFU at 1:8 dilution were
titrated, and the highest serum dilution showing
50% PFU reduction was regarded as the titer.
Antibodies neutralizing West Nile virus were
detected in 13 (2.1%) persons: 2.8% of 179 male
and 1.8% of 440 female. Persons with detectable
West Nile virus antibody were questioned about
their health history during the previous 5 years,
and their medical records were reviewed; none
recalled having had tickborne encephalitis
(Central-European encephalitis [CEE] virus is
the only other flavivirus present in Czechland) or
having been vaccinated against CEE or yellow
fever virus. Titers of PRN antibodies to CEEV
were all below 16. Two of the seropositive
persons had traveled abroad during the last 5
years: one to Croatia in 1996, and one to South
Australia during 1951 to 1994.
Paired serum samples were obtained from 72
of the 619 persons examined. A significant
increase (³4 times) in antibody titer against West
Nile virus between the first (acute-phase) and
second (convalescent-phase) samples was de-
tected four times: in 2 of 41 young persons (£16
years of age) and in 2 of 31 adults (>16 years of
age). Among the four seroconverting persons,
only the two children had clinical symptoms
compatible with West Nile fever. A 9-year-old
boy had fever (39oC) for 4 days, sore throat,
headache, muscle ache, pronounced fatigue, and
nausea lasting approximately 6 days, with
recovery after 13 days. Neutralizing antibodies
to West Nile virus, Eg-101 and 97-103, were 64
and 32 on July 22 and 512 and 256 on August 4,
respectively. A 9-year-old girl had fever (38°C-
39°C) for 3 days, sore throat, headache, muscle
ache, pronounced fatigue, nausea, vomiting,
maculopapular rash (including flushed face),
and slightly enlarged inguinal lymph nodes. The
illness lasted approximately 7 days, with
complete recovery after 17 days. Neutralizing
antibodies to West Nile virus, Eg-101 and 97-103,
were 64 and 32 on August 6 and 256 and 128 on
August 20, respectively. Of the remaining nine
seropositive persons lacking paired serum
samples, one had severe headache, muscle ache,
prolonged fatigue, nausea, pain on eye move-
ment, maculopapular rash, and insomnia in
summer of 1997. Two other persons had had
summer fever (sore throat and lymphadenitis;
headache with pain on eye movement) in 1997.
The other persons who seroconverted did not
report any substantial illness. In total, clinical
symptoms in five persons are compatible with
West Nile fever.